These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 25974722)

  • 1. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C.
    Pfeil AM; Reich O; Guerra IM; Cure S; Negro F; Müllhaupt B; Lavanchy D; Schwenkglenks M
    PLoS One; 2015; 10(5):e0126984. PubMed ID: 25974722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.
    Cure S; Guerra I; Cammà C; Craxì A; Carosi G
    J Med Econ; 2015; 18(9):678-90. PubMed ID: 25891129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.
    Linas BP; Barter DM; Morgan JR; Pho MT; Leff JA; Schackman BR; Horsburgh CR; Assoumou SA; Salomon JA; Weinstein MC; Freedberg KA; Kim AY
    Ann Intern Med; 2015 May; 162(9):619-29. PubMed ID: 25820703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
    Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T
    Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy.
    Ruggeri M; Romano F; Basile M; Coretti S; Rolli FR; Drago C; Cicchetti A
    Appl Health Econ Health Policy; 2018 Oct; 16(5):711-722. PubMed ID: 30039348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.
    Saint-Laurent Thibault C; Moorjaney D; Ganz ML; Sill B; Hede S; Yuan Y; Gorsh B
    J Med Econ; 2017 Jul; 20(7):692-702. PubMed ID: 28294645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.
    Stahmeyer JT; Rossol S; Liersch S; Guerra I; Krauth C
    PLoS One; 2017; 12(1):e0169401. PubMed ID: 28046099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
    Saab S; Parisé H; Virabhak S; Wang A; Marx SE; Sanchez Gonzalez Y; Misurski D; Johnson S
    J Med Econ; 2016 Aug; 19(8):795-805. PubMed ID: 27063573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
    Chhatwal J; Kanwal F; Roberts MS; Dunn MA
    Ann Intern Med; 2015 Mar; 162(6):397-406. PubMed ID: 25775312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
    Saab S; Virabhak S; Parisé H; Johnson S; Wang A; Misurski D; Gonzalez YS; Juday T
    Adv Ther; 2016 Aug; 33(8):1316-30. PubMed ID: 27342742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.
    Restelli U; Alberti A; Lazzarin A; Bonfanti M; Nappi C; Croce D
    Eur J Health Econ; 2018 Jan; 19(1):37-44. PubMed ID: 28008546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
    Kawaguchi I; Chayama K; Gonzalez YS; Virabhak S; Mitchell D; Yuen C; Kumada H
    Adv Ther; 2020 Jan; 37(1):457-476. PubMed ID: 31808054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.
    Blázquez-Pérez A; San Miguel R; Mar J
    Pharmacoeconomics; 2013 Oct; 31(10):919-31. PubMed ID: 24000086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
    Lo AO; Chan HL; Wong VW; Wong GL
    J Gastroenterol Hepatol; 2017 May; 32(5):1071-1078. PubMed ID: 28449343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
    Chahal HS; Marseille EA; Tice JA; Pearson SD; Ollendorf DA; Fox RK; Kahn JG
    JAMA Intern Med; 2016 Jan; 176(1):65-73. PubMed ID: 26595724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients.
    Cure S; Guerra I; Dusheiko G
    J Viral Hepat; 2015 Nov; 22(11):882-9. PubMed ID: 25847572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
    Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
    J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Oral Regimens for Adolescents With Chronic Hepatitis C Virus Infection.
    Zhou H; Lu Y; Wu B; Che D
    Pediatr Infect Dis J; 2020 Jun; 39(6):e59-e65. PubMed ID: 32345829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
    Cammà C; Petta S; Cabibbo G; Ruggeri M; Enea M; Bruno R; Capursi V; Gasbarrini A; Alberti A; Craxì A;
    J Hepatol; 2013 Oct; 59(4):658-66. PubMed ID: 23707373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.